This Article Full Text (PDF) All Versions of this Article: 0269881106072750v1 21/7/728    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bozina, N. Articles by Sertic, J. Search for Related Content PubMed PubMed Citation Articles by Bozina, N. Articles by Sertic, J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Schizophrenia Social Bookmarking                         What's this?

Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients

Clinical Institute of Laboratory Diagnosis, Zagreb University School of Medicine and Clinical Hospital Centre, Zagreb, Croatia, nbozina{at}net.hr

Vesna Medved

Department of Psychiatry, Zagreb University Hospital Centre, Zagrab, Croatia

Martina Rojnic Kuzman

Department of Psychiatry, Zagreb University Hospital Centre, Zagrab, Croatia

Ivica Sain

'Sveti Ivan' Psychiatric Hospital, Zagreb, Croatia

Jadranka Sertic

Clinical Institute of Laboratory Diagnosis, Zagreb University School of Medicine and Clinical Hospital Centre, Zagreb, Croatia

We investigated the relationships between L/S promoter (SERTPR) and l/s intron2 (SERTin2) genetic variants of serotonin transporter (SERT) polymorphisms with olanzapine-induced weight gain and treatment response in 94 female schizophrenic patients treated with olanzapine for up to 3 months. Body mass index (BMI) was calculated for each patient prior to olanzapine administration and 3 months afterwards. To assess and evaluate improvement of clinical psychotic symptoms and therapeutic response to the antipsychotic, all patients were rated using the Positive and Negative Syndrome ScaLe (PANSS). Overall, the presence of S SERTPR allelic variant and SS genotype was associated with significantly higher weight gain in subjects who were non-obese at the time of admission. The presence of L SERTPR variant was associated with significantly better treatment response measured with total PANSS and general PANSS subscale, while the presence of l SERTin2 variant determined better treatment response only in several items. No evidence of linkage disequilibrium between the two loci was found in the sample. These findings identify genetic factors associated with oLanzapine-induced weight gain and treatment response in femaLe schizophrenic patients.

Key Words: olanzapine • schizophrenia • genetics • serotonin transporters • weight gain • treatment response

This version was published on September 1, 2007

Journal of Psychopharmacology, Vol. 21, No. 7, 728-734 (2007)
DOI: 10.1177/0269881106072750


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. Medved, M. Kuzman, N. Jovanovic, J. Grubisin, and T. Kuzman Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up J Psychopharmacol, November 1, 2009; 23(8): 915 - 922. [Abstract] [PDF]